Binge Eating Disorder Clinical Trial
Official title:
Follow-Up Extension to the Family Study of Binge Eating Disorder
Verified date | April 2012 |
Source | Mclean Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
This study involves a 2.5 and 5 year follow-up interview for individuals who participated in the initial family study of binge eating disorder. The study includes individuals with and without eating disorder as well as their first degree relatives. As part of the study, participants will be interviewed about their current psychiatric and medical symptoms, their blood pressure will be measured, and laboratory specimens will be obtained.
Status | Completed |
Enrollment | 268 |
Est. completion date | November 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Individuals with or without binge eating disorder and their family members who participated in the initial family study of binge eating disorder and agree to be followed up at 2.5 and 5 years. Exclusion Criteria: - Unwilling or unable to participate in the follow-up study. |
Observational Model: Cohort, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | McLean Hospital | Belmont | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Mclean Hospital | Ortho-McNeil Janssen Scientific Affairs, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Diagnosis of Dyslipidemia | The number of participants to acquire a new diagnosis of high cholesterol (dyslipidemia) over the course of the baseline to five-year followup. | Baseline to 5 years | No |
Primary | Incidence of Diagnosis of Hypertension | The number of participants to acquire a new diagnosis of high blood pressure(hypertension) over the course of the baseline to five-year followup. | Baseline to 5 years | No |
Primary | Incidence of Diagnosis of Type 2 Diabetes | The number of participants to acquire a new diagnosis of Type 2 Diabetes over the course of the baseline to five-year followup. | Baseline to 5 years | No |
Primary | Incidence of Diagnosis of Any Metabolic Syndrome Component | The number of participants to acquire a new diagnosis of one component of metabolic syndrome. Metabolic syndrome can include abdominal obesity, high blood pressure, high cholesterol, etc. | Baseline to 5 years | No |
Primary | Incidence of Diagnosis of Two or More Metabolic Syndrome Components | The number of participants to acquire a new diagnosis of two or more components of metabolic syndrome. Metabolic syndrome can include abdominal obesity, high blood pressure, high cholesterol, etc. | Baseline to 5 years | No |
Primary | Incidence of Diagnosis of Three or More Metabolic Syndrome Components | The number of participants to acquire a new diagnosis of three or more components of metabolic syndrome. Metabolic syndrome can include abdominal obesity, high blood pressure, high cholesterol, etc. | Baseline to 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
Active, not recruiting |
NCT01837953 -
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
|
N/A | |
Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT01552759 -
Appetite Hormones in Binge Eating Disorder
|
N/A | |
Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT03107026 -
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 |